BCRX
BioCryst Pharmaceuticals, Inc. · Healthcare
Insiders sold $4.1M of BioCryst Pharmaceuticals, Inc. in the last 12 months and bought none
BCRX over the last year
BCRX after insider buys
3 months after each buy, from the first price a copier could get.
3 buys since 2016 with 3 months of prices.
Congress
Members reported 4 trades in BCRX since 2023.
Every filing
93 insider filings since 2016, newest first
Amy E Mckee · Director
Alane P Barnes · General Counsel
Theresa Heggie · Director
Alane P Barnes · General Counsel
Alane P Barnes · General Counsel
Alane P Barnes · General Counsel
Alane P Barnes · General Counsel
Amy E Mckee · Director
Machelle Sanders · Director
Theresa Heggie · Director
Alan G Levin · Director
Nancy J Hutson · Director
Vincent Milano · Director
Anthony Doyle · CFO
Helen M. Thackray · Chief R, D Officer
Steven K Galson · Director
Alane P Barnes · General Counsel
Jon P Stonehouse · President and CEO
Charles K Gayer · Chief Commercial Officer
Machelle Sanders · Director
Nancy J Hutson · Director
Helen M. Thackray · Chief R, D Officer
Jon P Stonehouse · President and CEO
Jon P Stonehouse · President and CEO
Helen M. Thackray · Chief R, D Officer
Anthony Doyle · CFO
Charles K Gayer · Chief Commercial Officer
Alane P Barnes · General Counsel
Michael L Jones · Exec. Dir, Finance - PAO
Jon P Stonehouse · President and CEO
Yarlagadda S Babu · Chief Discovery Officer
George B Abercrombie · Director
Helen M. Thackray · Chief R, D Officer
William P Sheridan · Chief Medical Officer
Yarlagadda S Babu · Chief Discovery Officer
Michael L Jones · Exec. Dir, Finance - PAO
George B Abercrombie · Director
Jon P Stonehouse · President and CEO
Vincent Milano · Director
Anthony Doyle · CFO
George B Abercrombie · Director
Nancy J Hutson · Director
George B Abercrombie · Director
Kenneth B Lee Jr · Director
George B Abercrombie · Director
George B Abercrombie · Director
Nancy J Hutson · Director
William P Sheridan · Chief Medical Officer
George B Abercrombie · Director
Alane P Barnes · General Counsel
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.